138 related articles for article (PubMed ID: 23259428)
1. Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents?
English DP; Roque DM; Santin AD
Expert Rev Anticancer Ther; 2013 Jan; 13(1):63-74. PubMed ID: 23259428
[TBL] [Abstract][Full Text] [Related]
2. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype.
Lopus M; Smiyun G; Miller H; Oroudjev E; Wilson L; Jordan MA
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1013-24. PubMed ID: 26416565
[TBL] [Abstract][Full Text] [Related]
4. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
Yardley DA
Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
[TBL] [Abstract][Full Text] [Related]
5. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M
J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783
[TBL] [Abstract][Full Text] [Related]
6. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
7. Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.
Roque DM; Bellone S; English DP; Buza N; Cocco E; Gasparrini S; Bortolomai I; Ratner E; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Santin AD
Cancer; 2013 Jul; 119(14):2582-92. PubMed ID: 23585021
[TBL] [Abstract][Full Text] [Related]
8. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents.
Nicoletti MI; Valoti G; Giannakakou P; Zhan Z; Kim JH; Lucchini V; Landoni F; Mayo JG; Giavazzi R; Fojo T
Clin Cancer Res; 2001 Sep; 7(9):2912-22. PubMed ID: 11555610
[TBL] [Abstract][Full Text] [Related]
9. Wild-type class I beta-tubulin sensitizes Taxol-resistant breast adenocarcinoma cells harboring a beta-tubulin mutation.
Wiesen KM; Xia S; Yang CP; Horwitz SB
Cancer Lett; 2007 Nov; 257(2):227-35. PubMed ID: 17869412
[TBL] [Abstract][Full Text] [Related]
10. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?
Sève P; Dumontet C
Lancet Oncol; 2008 Feb; 9(2):168-75. PubMed ID: 18237851
[TBL] [Abstract][Full Text] [Related]
11. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
Sève P; Isaac S; Trédan O; Souquet PJ; Pachéco Y; Pérol M; Lafanéchère L; Penet A; Peiller EL; Dumontet C
Clin Cancer Res; 2005 Aug; 11(15):5481-6. PubMed ID: 16061864
[TBL] [Abstract][Full Text] [Related]
12. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.
Umezu T; Shibata K; Kajiyama H; Terauchi M; Ino K; Nawa A; Kikkawa F
Int J Gynecol Pathol; 2008 Apr; 27(2):207-12. PubMed ID: 18317222
[TBL] [Abstract][Full Text] [Related]
13. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
[TBL] [Abstract][Full Text] [Related]
14. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
Vahdat L
Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
[TBL] [Abstract][Full Text] [Related]
15. Resistance to the tubulin-binding agents in renal cell carcinoma: no mutations in the class I beta-tubulin gene but changes in tubulin isotype protein expression.
Ferguson RE; Taylor C; Stanley A; Butler E; Joyce A; Harnden P; Patel PM; Selby PJ; Banks RE
Clin Cancer Res; 2005 May; 11(9):3439-45. PubMed ID: 15867246
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of natural product microtubule stabilizers on microtubule assembly: single agent and combination studies with taxol, epothilone B, and discodermolide.
Gertsch J; Meier S; Müller M; Altmann KH
Chembiochem; 2009 Jan; 10(1):166-75. PubMed ID: 19058273
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
Kadra G; Finetti P; Toiron Y; Viens P; Birnbaum D; Borg JP; Bertucci F; Gonçalves A
Breast Cancer Res Treat; 2012 Apr; 132(3):1035-47. PubMed ID: 21792624
[TBL] [Abstract][Full Text] [Related]
18. Preclinical investigations with epothilones in breast cancer models.
Burris HA
Semin Oncol; 2008 Apr; 35(2 Suppl 2):S15-21; quiz S39. PubMed ID: 18410795
[TBL] [Abstract][Full Text] [Related]
19. Cytoskeletal alterations that confer resistance to anti-tubulin chemotherapeutics.
Kanakkanthara A; Teesdale-Spittle PH; Miller JH
Anticancer Agents Med Chem; 2013 Jan; 13(1):147-58. PubMed ID: 22583426
[TBL] [Abstract][Full Text] [Related]
20. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
Rivera E; Lee J; Davies A
Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
